



(51) International Patent Classification:

C07D 213/82 (2006.01) C07C 233/47 (2006.01)
C07D 239/36 (2006.01) A61K 31/21 (2006.01)
C07D 261/18 (2006.01) A61K 31/435 (2006.01)
C07D 271/06 (2006.01)

(21) International Application Number:

PCT/EP2010/057247

(22) International Filing Date:

26 May 2010 (26.05.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/181,756 28 May 2009 (28.05.2009) US
61/263,145 20 November 2009 (20.11.2009) US
61/324,943 16 April 2010 (16.04.2010) US

(71) Applicants (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **SUN, Robert** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COPPOLA, Gary Mark** [US/US]; 18 Aldersgate Circle, Budd Lake, New Jersey 07828 (US). **IWAKI, Yuki** [JP/US]; Novartis Institutes for BioMedical Research, Inc., 400 Technology Square, Cambridge, Massachusetts 02139 (US). **KARKI, Rajeshri Ganesh** [IN/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **KAWANAMI,**

Toshio [JP/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **KSANDER, Gary Michael** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **MOGI, Muneto** [JP/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US).

(74) Agent: **VOEGELI-LANGE, Regina**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

[Continued on next page]

(54) Title: SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS



Formula I'

(57) Abstract: The present invention provides a compound of formula I' or a pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁵, B¹, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.



— *as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*